NASDAQ:FATEFate Therapeutics Stock Price, Forecast & News

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FATE stock has increased by 36.3% and is now trading at $32.43. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fate Therapeutics.

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Fate Therapeutics.

Fate Therapeutics Inc (NASDAQ:FATE) posted its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $2.52 million during the quarter, compared to the consensus estimate of $1.69 million. Fate Therapeutics had a negative return on equity of 52.08% and a negative net margin of 1,059.44%. Fate Therapeutics's quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.30) EPS. View Fate Therapeutics' earnings history.

17 brokerages have issued 12 month target prices for Fate Therapeutics' stock. Their forecasts range from $25.00 to $57.00. On average, they anticipate Fate Therapeutics' share price to reach $35.88 in the next year. This suggests a possible upside of 10.6% from the stock's current price. View analysts' price targets for Fate Therapeutics.

News headlines about FATE stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fate Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutFate Therapeutics.

Some companies that are related to Fate Therapeutics include Qiagen (QGEN), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), bluebird bio (BLUE) and Halozyme Therapeutics (HALO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Juno Therapeutics (JUNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), TG Therapeutics (TGTX) and Clovis Oncology (CLVS).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.36%), Victory Capital Management Inc. (4.58%), Victory Capital Management Inc. (4.58%), Janus Henderson Group PLC (4.34%), State Street Corp (3.25%) and Franklin Resources Inc. (1.51%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View institutional ownership trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Pictet Asset Management Ltd., Franklin Resources Inc., Sofinnova Investments Inc., Morgan Stanley, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko. View insider buying and selling activity for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Federated Hermes Inc., Invesco Ltd., Asymmetry Capital Management L.P., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., and State Street Corp. View insider buying and selling activity for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $32.43.

Fate Therapeutics has a market capitalization of $2.52 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]